EGFR and non-small cell lung carcinoma: In addition, we found that, in ES-NSCLC, PD-L1 expression levels were lower in EGFR mutated tumors (p = 0.02) compared to wild-type tumors, whereas no differences were observed in relation to other targetable alterations.